Galmed Pharmaceutica (GLMD)

$0.67 +0.00 (0.69%)
Market Cap 1.18M
Revenue (ttm) 0.00
Net Income (ttm) -7.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,800
Avg Vol 139,670
Day's Range N/A - N/A
Shares Out 1.65M
Stochastic %K 4%
Beta 0.35
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
BankOnTheFuture
BankOnTheFuture Feb. 3 at 7:00 PM
$GLMD The clinical trial with aramchol/Bayer regenerib should be starting any day now
1 · Reply
getsometoday
getsometoday Feb. 3 at 4:49 PM
$GLMD overdue for a PR let’s go !
0 · Reply
Lowlyme
Lowlyme Feb. 3 at 2:06 PM
$GLMD Try it for five years. LOL GL
0 · Reply
BankOnTheFuture
BankOnTheFuture Feb. 2 at 9:31 PM
$GLMD What a bullshit close. Was looking like we might close even or in the green earlier this afternoon
1 · Reply
getsometoday
getsometoday Feb. 2 at 9:14 PM
$GLMD checking this sp is like a daily kick in the shins
1 · Reply
madan_shatri
madan_shatri Feb. 2 at 1:28 PM
$GLMD I hope a hostile takeover can save us 🙏 Pre market down 7% to new low of $0.66. $3.X million to $4.X million market cap could be a great attraction for a hostile take over. But if its heavily diluted already then could be just a matter of under $1.00 million market cap. Wow ! Disgraceful
2 · Reply
BankOnTheFuture
BankOnTheFuture Feb. 1 at 6:15 PM
$GLMD This is interesting. A law firm named Strand Hanson in Dec 2025 won $7M over an unpaid pharma merger fee from Conduit Pharmaceuticals even though the merger didn't proceed. Conduit was going to acquire Galmed... for $720M.
3 · Reply
Lowlyme
Lowlyme Jan. 31 at 2:30 PM
$GLMD Allen's only business plan is to maintain his million dollar salary. He even "incentivezed" himself by issuing himself more shares. We got diluted. He didn't. He also periodically cyphons off capital meant for trials and "disappears" it. This has been going on for years and years. He gets richer and richer. We get poorer. This will stay in noncompliance. CEO has lost all credibility. But, as always, GLTA.
0 · Reply
gabbs
gabbs Jan. 30 at 10:17 PM
$GLMD told ya
1 · Reply
madan_shatri
madan_shatri Jan. 30 at 5:40 PM
$GLMD I would stay away from this stock. Won't be doing avg down Toxic !!
0 · Reply
Latest News on GLMD
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026, 4:15 PM EST - 4 days ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 2 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 2 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 2 months ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 2 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 2 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 2 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 5 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 5 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 9 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 9 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 9 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 10 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 10 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 10 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 10 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 11 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022, 7:30 AM EDT - 4 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 1:56 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed announces positive results of Phase 1 study of Amilo-5MER

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

BankOnTheFuture
BankOnTheFuture Feb. 3 at 7:00 PM
$GLMD The clinical trial with aramchol/Bayer regenerib should be starting any day now
1 · Reply
getsometoday
getsometoday Feb. 3 at 4:49 PM
$GLMD overdue for a PR let’s go !
0 · Reply
Lowlyme
Lowlyme Feb. 3 at 2:06 PM
$GLMD Try it for five years. LOL GL
0 · Reply
BankOnTheFuture
BankOnTheFuture Feb. 2 at 9:31 PM
$GLMD What a bullshit close. Was looking like we might close even or in the green earlier this afternoon
1 · Reply
getsometoday
getsometoday Feb. 2 at 9:14 PM
$GLMD checking this sp is like a daily kick in the shins
1 · Reply
madan_shatri
madan_shatri Feb. 2 at 1:28 PM
$GLMD I hope a hostile takeover can save us 🙏 Pre market down 7% to new low of $0.66. $3.X million to $4.X million market cap could be a great attraction for a hostile take over. But if its heavily diluted already then could be just a matter of under $1.00 million market cap. Wow ! Disgraceful
2 · Reply
BankOnTheFuture
BankOnTheFuture Feb. 1 at 6:15 PM
$GLMD This is interesting. A law firm named Strand Hanson in Dec 2025 won $7M over an unpaid pharma merger fee from Conduit Pharmaceuticals even though the merger didn't proceed. Conduit was going to acquire Galmed... for $720M.
3 · Reply
Lowlyme
Lowlyme Jan. 31 at 2:30 PM
$GLMD Allen's only business plan is to maintain his million dollar salary. He even "incentivezed" himself by issuing himself more shares. We got diluted. He didn't. He also periodically cyphons off capital meant for trials and "disappears" it. This has been going on for years and years. He gets richer and richer. We get poorer. This will stay in noncompliance. CEO has lost all credibility. But, as always, GLTA.
0 · Reply
gabbs
gabbs Jan. 30 at 10:17 PM
$GLMD told ya
1 · Reply
madan_shatri
madan_shatri Jan. 30 at 5:40 PM
$GLMD I would stay away from this stock. Won't be doing avg down Toxic !!
0 · Reply
TradeSun
TradeSun Jan. 29 at 7:10 PM
$GUTS As of PR from January -> $ 85M cash on hand, (end of q3 $ 77M) so cash runway for one more year. MCap $ 90M now. Traded on cash now. Usually a good sign for a bounce, imo. But pretty hard to raise cash at this SP level. Hope for you guys to see a fat bounce here!!! $MTVA $ALT $GLMD $BIOBI*ch
1 · Reply
BankOnTheFuture
BankOnTheFuture Jan. 29 at 5:37 PM
$GLMD Guess the speculators who bought in over the last week assuming surely management wouldn't let the 30 days elapse are now exiting their positions. Because management let the 30 days elapse w/o doing anything. Exasperating.
2 · Reply
Morpomex
Morpomex Jan. 28 at 4:57 PM
$GLMD Still here. Still waiting.
1 · Reply
Lowlyme
Lowlyme Jan. 28 at 11:18 AM
$GLMD Me picking stocks.
0 · Reply
getsometoday
getsometoday Jan. 27 at 8:30 PM
$GLMD looks like Allen is buying some shares
1 · Reply
madan_shatri
madan_shatri Jan. 27 at 2:52 PM
$GLMD so after 4 PM tomorrow, GLMD will be receiving delisting notice and an automatic 6 months of time grace period to fulfill the listing conditions Company will PR this update sometimes end of next week. Usually its 3 to 7 business days for the company to release the notice of delisting PR Good Luck 👍
1 · Reply
Lowlyme
Lowlyme Jan. 27 at 12:52 AM
$GLMD
0 · Reply
Lowlyme
Lowlyme Jan. 26 at 7:44 PM
$GLMD Come on AW. Weigh in! LOL
0 · Reply
madan_shatri
madan_shatri Jan. 25 at 6:04 PM
$GLMD Are we entering into fearful times of collapse of stock market ? I am starting to get some anxiety. Possible dollar & stock market collapse ? Worldwide chaos is getting louder & louder 🤔
1 · Reply
madan_shatri
madan_shatri Jan. 24 at 3:48 AM
$GLMD 27 days under $1.00 are gone. Only 3 more trading days are left
1 · Reply
madan_shatri
madan_shatri Jan. 23 at 4:14 PM
$GLMD only thing comes in mind for this stock is complete pos !
1 · Reply
Lowlyme
Lowlyme Jan. 23 at 1:57 AM
$GLMD Just look at the chart above.
0 · Reply